Duquesne Family Office’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Duquesne Family Office’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-58,997	Closed	-$2.24M	–	76
2022 Q4	$2.24M	Hold	58,997	–	–	0.11%	50
2022 Q3	$1.48M	Hold	58,997	–	–	0.08%	59
2022 Q2	$1.79M	Hold	58,997	–	–	0.13%	35
2022 Q1	$1.93M	Sell	58,997 -347,267	-85%	-$10.3M	0.08%	48
2021 Q4	$10.7M	Sell	406,264 -288,769	-42%	-$22.3M	0.39%	27
2021 Q3	$69.9M	Buy	695,033 +57,689	+9%	+$6.76M	2.27%	12
2021 Q2	$90.2M	Sell	637,344 -112,553	-15%	-$12.7M	2.23%	14
2021 Q1	$74.8M	Hold	749,897	–	–	1.65%	17
2020 Q4	$92.7M	Buy	749,897 +205,996	+38%	+$27.1M	2.5%	13
2020 Q3	$53M	Buy	543,901 +11,023	+2%	+$1.38M	1.54%	19
2020 Q2	$83.1M	Buy	532,878 +1,000	+0.2%	+$152K	2.54%	14
2020 Q1	$76.8M	Buy	531,878 +105,159	+25%	+$20.3M	3.11%	11
2019 Q4	$87.2M	Buy	426,719 +253,434	+146%	+$46.2M	2.56%	12
2019 Q3	$13.9M	Buy	+173,285	New	+$14.7M	0.54%	30

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Duquesne Family Office's RETA Position: Q1 2023 in Review

Duquesne Family Office sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 58,997 shares — an estimated $2.24M sold.

Duquesne Family Office first reported a position in RETA in Q3 2019 and held it in 14 quarters. The position peaked at $92.7M in Q4 2020. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Duquesne Family Office reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Duquesne Family Office sold 58,997 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $2.24M.
Duquesne Family Office first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 14 quarters.
Duquesne Family Office's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $92.7M in Q4 2020.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Duquesne Family Office's 13F filing for Q1 2023, filed 15 May 2023.